MX2021007740A - Inhibidor de se?al de miostatina. - Google Patents
Inhibidor de se?al de miostatina.Info
- Publication number
- MX2021007740A MX2021007740A MX2021007740A MX2021007740A MX2021007740A MX 2021007740 A MX2021007740 A MX 2021007740A MX 2021007740 A MX2021007740 A MX 2021007740A MX 2021007740 A MX2021007740 A MX 2021007740A MX 2021007740 A MX2021007740 A MX 2021007740A
- Authority
- MX
- Mexico
- Prior art keywords
- signal inhibitor
- myostatin signal
- myostatin
- inhibitor
- acvr2b
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona un nuevo procedimiento para inhibir la señalización de miostatina al orientarse a ACVR2B en el nivel de ARNm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1821269.6A GB201821269D0 (en) | 2018-12-28 | 2018-12-28 | Myostatin signal inhibitor |
PCT/JP2019/051651 WO2020138509A1 (en) | 2018-12-28 | 2019-12-26 | Myostatin signal inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007740A true MX2021007740A (es) | 2021-08-05 |
Family
ID=65364695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007740A MX2021007740A (es) | 2018-12-28 | 2019-12-26 | Inhibidor de se?al de miostatina. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220119818A1 (es) |
EP (1) | EP3902916A1 (es) |
JP (1) | JP2022516207A (es) |
KR (1) | KR20210110593A (es) |
CN (1) | CN113272429A (es) |
AU (1) | AU2019415399A1 (es) |
BR (1) | BR112021012488A2 (es) |
CA (1) | CA3122475A1 (es) |
CL (3) | CL2021001712A1 (es) |
CO (1) | CO2021008091A2 (es) |
EC (1) | ECSP21046159A (es) |
GB (1) | GB201821269D0 (es) |
IL (1) | IL284342A (es) |
MX (1) | MX2021007740A (es) |
PE (1) | PE20211732A1 (es) |
PH (1) | PH12021551187A1 (es) |
SG (1) | SG11202106511UA (es) |
TW (1) | TW202039848A (es) |
WO (1) | WO2020138509A1 (es) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
JP3398378B2 (ja) | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体,デバイス及び医薬組成物 |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP1811024A1 (en) | 2004-10-05 | 2007-07-25 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna and medicinal composition |
EP1886688A4 (en) | 2005-05-30 | 2013-01-09 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING PREPARATION OF A NUCLEIC ACID-CONTAINING COMPLEX |
DK2024499T3 (da) | 2006-05-10 | 2018-01-29 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske intersubunit-koblinger |
CN101121933A (zh) * | 2006-08-11 | 2008-02-13 | 中国科学院上海生命科学研究院 | 用于激酶基因过表达相关疾病的siRNA |
JP5347510B2 (ja) | 2007-02-05 | 2013-11-20 | 日本新薬株式会社 | ポリエチレングリコール誘導体 |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
US8906877B2 (en) * | 2009-02-20 | 2014-12-09 | GenRemedy, LLC | Method for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
US8293881B2 (en) * | 2009-06-12 | 2012-10-23 | Acceleron Pharma Inc. | Isolated nucleic acid encoding a truncated ActRIIB fusion protein |
TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
US20140088174A1 (en) * | 2011-04-05 | 2014-03-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Compounds and methods for altering activin receptor-like kinase signaling |
KR102183273B1 (ko) | 2011-05-05 | 2020-11-27 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
KR20220045091A (ko) | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법 |
IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulation of hbv and ttr expression |
US10808246B2 (en) | 2013-07-11 | 2020-10-20 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
CN113105559A (zh) | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
WO2015105083A1 (ja) | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
GB201421379D0 (en) * | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
KR20240035901A (ko) | 2015-05-19 | 2024-03-18 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
EP3323893A4 (en) | 2015-07-16 | 2019-03-27 | Kyowa Hakko Kirin Co., Ltd. | BETA2GPI GENE EXPRESSION-INHIBITING NUCLEIC ACID COMPLEX |
UA123359C2 (uk) * | 2015-09-15 | 2021-03-24 | Ніппон Шин'Яку Ко., Лтд. | Антисенсова нуклеїнова кислота |
EP3351634A4 (en) * | 2015-09-16 | 2019-05-08 | Nippon Shinyaku Co., Ltd. | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF AMYOTROPHY |
BR112018007066A2 (pt) * | 2015-10-09 | 2018-10-23 | Sarepta Therapeutics Inc | composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados |
CN110636866A (zh) | 2016-12-19 | 2019-12-31 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
SG10202100491QA (en) | 2016-12-19 | 2021-02-25 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
HUE059843T2 (hu) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exonátugró oligomerkonjugátumok izomdisztrófiára |
US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
-
2018
- 2018-12-28 GB GBGB1821269.6A patent/GB201821269D0/en not_active Ceased
-
2019
- 2019-12-26 US US17/417,436 patent/US20220119818A1/en active Pending
- 2019-12-26 CN CN201980085589.0A patent/CN113272429A/zh active Pending
- 2019-12-26 WO PCT/JP2019/051651 patent/WO2020138509A1/en active Application Filing
- 2019-12-26 PE PE2021001062A patent/PE20211732A1/es unknown
- 2019-12-26 CA CA3122475A patent/CA3122475A1/en active Pending
- 2019-12-26 EP EP19848821.5A patent/EP3902916A1/en active Pending
- 2019-12-26 AU AU2019415399A patent/AU2019415399A1/en active Pending
- 2019-12-26 KR KR1020217020055A patent/KR20210110593A/ko active Search and Examination
- 2019-12-26 SG SG11202106511UA patent/SG11202106511UA/en unknown
- 2019-12-26 JP JP2021561143A patent/JP2022516207A/ja active Pending
- 2019-12-26 TW TW108148268A patent/TW202039848A/zh unknown
- 2019-12-26 BR BR112021012488-8A patent/BR112021012488A2/pt unknown
- 2019-12-26 MX MX2021007740A patent/MX2021007740A/es unknown
-
2021
- 2021-05-24 PH PH12021551187A patent/PH12021551187A1/en unknown
- 2021-06-21 CO CONC2021/0008091A patent/CO2021008091A2/es unknown
- 2021-06-23 IL IL284342A patent/IL284342A/en unknown
- 2021-06-25 EC ECSENADI202146159A patent/ECSP21046159A/es unknown
- 2021-06-25 CL CL2021001712A patent/CL2021001712A1/es unknown
-
2023
- 2023-06-27 CL CL2023001902A patent/CL2023001902A1/es unknown
- 2023-06-27 CL CL2023001901A patent/CL2023001901A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019415399A1 (en) | 2021-06-03 |
EP3902916A1 (en) | 2021-11-03 |
CO2021008091A2 (es) | 2021-06-30 |
CL2023001901A1 (es) | 2023-12-15 |
US20220119818A1 (en) | 2022-04-21 |
PH12021551187A1 (en) | 2022-01-03 |
KR20210110593A (ko) | 2021-09-08 |
CL2021001712A1 (es) | 2022-01-07 |
CN113272429A (zh) | 2021-08-17 |
BR112021012488A2 (pt) | 2021-09-08 |
WO2020138509A1 (en) | 2020-07-02 |
PE20211732A1 (es) | 2021-09-06 |
JP2022516207A (ja) | 2022-02-24 |
CA3122475A1 (en) | 2020-07-02 |
CL2023001902A1 (es) | 2023-12-15 |
ECSP21046159A (es) | 2021-07-30 |
GB201821269D0 (en) | 2019-02-13 |
IL284342A (en) | 2021-08-31 |
SG11202106511UA (en) | 2021-07-29 |
TW202039848A (zh) | 2020-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550546A1 (en) | Dispenser having a cartridge holder | |
MX2020004084A (es) | Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion. | |
IL282468A (en) | 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8 | |
MX2017000363A (es) | Inhibicion de la via de notch. | |
PH12017501523A1 (en) | Selective bace1 inhibitors | |
IL281483A (en) | Peptidase 9X-specific ubiquitin inhibition | |
MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
MX2018015697A (es) | Composición de alimentación que comprende una proteasa ácida. | |
MX2020014097A (es) | Lipidos novedosos. | |
PH12020500341A1 (en) | Pentacyclic compound | |
MX2020003706A (es) | Aminoimidazopiridazinas como inhibidores de cinasa. | |
ECSP18009366A (es) | Antagonistas del receptor de cgrp | |
PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
MX2016009245A (es) | Dispositivo de escudo protector para riel de traslacion. | |
MX2020003707A (es) | Instalacion de montaje de cabeza de pozo. | |
MX2020004228A (es) | Capa resistente al desgaste. | |
SG10202106560TA (en) | Erroneous mounting prevention system | |
PH12021551187A1 (en) | Myostatin signal inhibitor | |
MX2018003903A (es) | Compuesto biciclico y uso del mismo para inhibicion de suv39h2. | |
SG10201810263QA (en) | Nampt inhibitors and methods | |
MX2017003728A (es) | Sistema mejorador de sabor. | |
MX2017012041A (es) | Sistema nivelador de muebles. | |
CA187928S (en) | Chain for eyeglasses | |
CA195947S (en) | Electronic cigarette |